![]() ![]() Mediwhale’s Reti-Intelligence technology that focuses on heart health (Reti-CVD) is in pre-application stages for FDA approval. The company is currently active in the HeartX health tech accelerator program in Arkansas, was an innovation honoree at CES and gave presentations at the ASN Kidney Week conference and the American Heart Association Scientific Session, all in 2022. Mediwhale, based in South Korea, is no stranger to the U.S. ![]() Mediwhale was selected based on its cutting-edge technology and business growth, even without a Stanford connection. StartX is a highly selective program, with a rigorous interview process. The program offers a wide range of services and resources, including mentorship, educational workshops, access to investors, and a community of like-minded entrepreneurs. ![]() StartX is dedicated to helping entrepreneurs bring their innovative ideas to life by providing what they need to grow and succeed. The program is currently underway and runs through April, and Mediwhale will continue to be an active StartX community member afterwards. Kevin Choi, CEO of MediwhalePALO ALTO, CALIFORNIA, UNITED STATES, Febru/ / - Mediwhale, the AI-empowered health diagnostics company that uses retina scans to diagnose future cardiac and kidney disorder risk quickly and easily, announced today it has been accepted into the 2023 cohort of StartX, an exclusive accelerator program affiliated with Stanford University and Stanford Healthcare. ![]()
0 Comments
Leave a Reply. |